Extended-Release Niacin Decreases ApoB-48 Concentration in Type 2 Diabetes
In type 2 diabetes, extended-release niacin lowers apolipoprotein B-48 in type 2 diabetes.
(HealthDay News) — For patients with type 2 diabetes, a statin plus extended-release niacin lowers apolipoprotein B-48 (apoB-48) concentration compared with a statin alone, according to a study published in Diabetes, Obesity and Metabolism.
Jing Pang, from the University of Western Australia in Perth, and colleagues examined the effect of extended-release niacin on apoB-48 kinetics in 12 statin-treated men with type 2 diabetes. Participants were randomly allocated to receive 12 weeks of rosuvastatin or rosuvastatin plus extended-release niacin and then crossed over to the alternative treatment. At the end of each treatment period, postprandial metabolic studies were performed and apoB-48 kinetics were determined.
The researchers found that the apoB-48 concentration was lower with extended-release niacin vs statin alone (P=.03). Extended-release niacin treatment also correlated with significantly lower postprandial triglyceride and apoB-48 area under the curve (AUC; P<.05), with no change seen in triglyceride and apoB-48 incremental AUC.
Extended-release niacin treatment was associated with lower apoB-48 secretion rate in the basal state (P=.04) and a lower number of apoB-48 containing particles secreted in response to fat load (P=.02). Extended-release niacin was not associated with alteration in apoB-48 fractional catabolic rates (P=.79).
"[Extended-release niacin] reduces apoB-48 concentration by lowering fasting and postprandial apoB-48 [secretion rate]," the researchers wrote. "This effect may be beneficial for lowering atherogenic postprandial lipoproteins and may provide cardiovascular disease risk benefit in patients with type 2 diabetes."
One author disclosed financial ties to Abbott, which provided the extended-release niacin for the study.